Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
If you are wondering whether Novo Nordisk stock is attractively priced right now, the key is to understand what the recent share price is actually implying about future expectations.
The stock last closed at US$45.80, with recent returns of 8.5% over 7 days and 24.1% over 30 days, but a 27.0% decline over 1 year and a 42.7% decline over 3 years.
These moves have come alongside ongoing attention on Novo Nordisk’s role in pharmaceuticals and biotech, including its position in treatments that remain central to many long term healthcare trends. This backdrop helps explain why sentiment can swing quickly as investors reassess what they are willing to pay for the stock.
On Simply Wall St’s valuation checks, Novo Nordisk scores 5 out of 6 for potential undervaluation. You can see the breakdown in the valuation score, which sets up a closer look at different valuation approaches and hints at a broader way to think about value that will be covered at the end of this article.
Find out why Novo Nordisk’s -27.0% return over the last year is lagging behind its peers.
Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value.
For Novo Nordisk, the model used is a 2 Stage Free Cash Flow to Equity approach. The company last reported trailing twelve month free cash flow of DKK 48.21b. Analyst projections and subsequent extrapolations by Simply Wall St point to free cash flow of DKK 103.29b in 2030, with intermediate years such as 2026 and 2027 projected at DKK 51.17b and DKK 73.61b respectively. Beyond the explicit analyst horizon, the model extends cash flows using estimated growth rates to complete the 10 year projection set.
Discounting these projected cash flows back to today gives an estimated intrinsic value of US$101.79 per share. Compared with the recent share price of US$45.80, the DCF output suggests that the stock trades at a 55.0% discount to this intrinsic value, indicating a meaningful gap between price and this particular cash flow based estimate.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 55.0%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.
NVO Discounted Cash Flow as at May 2026
Story Continues
Approach 2: Novo Nordisk Price vs Earnings
For profitable companies, the P/E ratio is a useful shorthand for what investors are currently willing to pay for each unit of earnings. It ties the share price directly to the earnings that support it, which many investors focus on when judging value.
What counts as a “normal” or “fair” P/E depends on how the market views the company’s growth prospects and risks. Higher expected growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually points to a lower P/E.
Novo Nordisk currently trades on a P/E of 10.74x. That sits below the Pharmaceuticals industry average of 16.69x and the peer group average of 23.12x. Simply Wall St also calculates a Fair Ratio of 23.82x, which is the P/E that would typically be expected given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio can be more informative than a simple comparison with peers or the industry because it adjusts for these company level characteristics. With the current P/E of 10.74x sitting well below the Fair Ratio of 23.82x, the multiple based view points to Novo Nordisk trading at a discount.
Result: UNDERVALUED
NYSE:NVO P/E Ratio as at May 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.
Upgrade Your Decision Making: Choose your Novo Nordisk Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in. A Narrative is simply your story about Novo Nordisk, written in numbers you care about, such as your view of future revenue, earnings and margins, and the fair value that follows from those assumptions. Instead of looking at valuation ratios in isolation, a Narrative connects what you believe about the business to a financial forecast, then to a fair value, and finally to a clear comparison with today’s share price. Narratives are available on Simply Wall St’s Community page, where millions of investors share and explore these story plus numbers combinations in an accessible format. You can use them to decide whether the stock suits you by comparing each Narrative’s fair value with the current price and seeing which story feels most realistic. Narratives are refreshed when new information such as earnings or news is added, so they do not stay frozen. For example, one Novo Nordisk Narrative might point to a much higher fair value while another, more cautious view, might imply a much lower figure based on different expectations for future cash flows.
Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!
NYSE:NVO Earnings & Revenue History as at May 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com